| dc.description.abstract | Background: Theoretically, lung cancer patients receiving treatment with EGFRTKI
will experience acquired resistance within 7-16 months from the start of
treatment, which is indicated by the appearance of exon 20 T790M mutations in
the patient. This will result in the EGFR-TKI treatment received so far being
ineffective, and cancer cells can develop again. This study aims to determine the
demographic profile and clinical profile of the incidence of acquired resistance by
using liquid biopsy examination in patients with lung adenocarcinoma who
received EGFR TKI therapy.
Methods: A descriptive study with a retrospective cohort design was carried out
at the Oncology Polyclinic at H Adam Malik Hospital Medan from October 2020
to January 2021. The subjects were all patients with lung cancer of the
adenocarcinoma type with histopathological, cytological or both who had
received therapy with EGFR TKI for more than 6 months. The method of droplet
digital polymerase chain reaction (ddPCR) was performed to detect EGFR exon
20 T790M mutations.
Results: A total of 31 patients met the requirements as subjects. It was found that
the majority of subjects were female (64.5%), aged 20-69 years (58%) and nonsmokers
(67.7%). The most common EGFR mutation was exon 19 deletion
(58.1%). Acquired resistance events were found in 10 subjects (32.3%). Patients
with acquired resistance were dominated by women (70%), without a history of
smoking (80%), with Gefitinib treatment (90%). The average length of time for
EGFR-TKI treatment until acquired resistance occurs is 12.6 months.
Conclusion: The incidence of acquired resistance was mainly found in women
without smoking history after 12.6 months of treatment with EGFR TKI. | en_US |
